Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
Total Valuation
Bright Minds Biosciences has a market cap or net worth of $859.37M. The enterprise value is $522.10M.
Market Cap$859.37M
Enterprise Value$522.10M
Share Statistics
Bright Minds Biosciences has 9,732,161 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,732,161
Owned by Insiders11.33%
Owned by Institutions36.97%
Financial Efficiency
Bright Minds Biosciences’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -16.94%.
Return on Equity (ROE)-0.15
Return on Assets (ROA)-0.14
Return on Invested Capital (ROIC)-16.94%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bright Minds Biosciences is ―. Bright Minds Biosciences’s PEG ratio is -0.27.
PE Ratio―
PS Ratio0.00
PB Ratio7.07
Price to Fair Value7.07
Price to FCF-66.78
Price to Operating Cash Flow-97.31
PEG Ratio-0.27
Income Statement
In the last 12 months, Bright Minds Biosciences had revenue of 0.00 and earned -12.23M in profits. Earnings per share was -1.78.
Revenue0.00
Gross Profit-76.87K
Operating Income-13.94M
Pretax Income-12.23M
Net Income-12.23M
EBITDA-12.12M
Earnings Per Share (EPS)-1.78
Cash Flow
In the last 12 months, operating cash flow was -8.69M and capital expenditures -5.00, giving a free cash flow of -8.69M billion.
Operating Cash Flow-8.69M
Free Cash Flow-8.69M
Free Cash Flow per Share-0.89
Dividends & Yields
Bright Minds Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta4.82
52-Week Price Change147.96%
50-Day Moving Average75.41
200-Day Moving Average47.80
Relative Strength Index (RSI)55.29
Average Volume (3m)102.09K
Important Dates
Bright Minds Biosciences upcoming earnings date is Feb 18, 2026, Before Open (Confirmed).
Last Earnings DateDec 24, 2025
Next Earnings DateFeb 18, 2026
Ex-Dividend Date―
Financial Position
Bright Minds Biosciences as a current ratio of 36.10, with Debt / Equity ratio of 0.15%
Current Ratio36.10
Quick Ratio36.10
Debt to Market Cap<0.01
Net Debt to EBITDA6.83
Interest Coverage Ratio-388.76
Taxes
In the past 12 months, Bright Minds Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bright Minds Biosciences EV to EBITDA ratio is -41.07, with an EV/FCF ratio of -57.26.
EV to Sales0.00
EV to EBITDA-41.07
EV to Free Cash Flow-57.26
EV to Operating Cash Flow-57.26
Balance Sheet
Bright Minds Biosciences has $82.91M in cash and marketable securities with $125.78K in debt, giving a net cash position of $82.78M billion.
Cash & Marketable Securities$82.91M
Total Debt$125.78K
Net Cash$82.78M
Net Cash Per Share$8.51
Tangible Book Value Per Share$11.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bright Minds Biosciences is $120.95, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$120.95
Price Target Upside37.44% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―